Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase I clinical trial

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase I clinical trial

The safety and immunogenicity of a new candidate tuberculosis (TB) vaccine, FP85A was evaluated alone and in heterologous prime-boost regimes with another candidate TB vaccine, MVA85A. This was an open label, non-controlled, non-randomized Phase I clinical trial. Healthy previously BCG-vaccinated ad...

Full description

Bibliographic Details
Main Authors: Rowland, Rosalind, Pathan, Ansar A., Satti, Iman, Poulton, Ian D., Matsumiya, Magali M. L., Whittaker, Megan, Minassian, Angela M., O’Hara, Geraldine A., Hamill, Matthew, Scott, Janet T., Harris, Stephanie A., Poyntz, Hazel C., Bateman, Cynthia, Meyer, Joel, Williams, Nicola, Gilbert, Sarah C., Lawrie, Alison M., Hill, Adrian V.S., McShane, Helen
Format: Online
Language:English
Published: Landes Bioscience 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667946/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667946/

Similar Items